Back to Journals » OncoTargets and Therapy » Volume 12

Diagnostic significance of miR-210 as a potential tumor biomarker of human cancer detection: an updated pooled analysis of 30 articles

Authors Feng S, He A, Wang D, Kang B

Received 20 August 2018

Accepted for publication 26 November 2018

Published 9 January 2019 Volume 2019:12 Pages 479—493


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr XuYu Yang

Song Feng,1,* Anbang He,2,* Deli Wang,1 Bin Kang1

1Department of Bone and Joint Surgery, Peking University Shenzhen Hospital, Peking University Shenzhen, Shenzhen 518038, Guangdong, China; 2Department of Urology, Peking University First Hospital, The Institute of Urology, Peking University National Urological Cancer Centre, Beijing 100034, China

*These authors contributed equally to this work

Abstract: A large number of studies have explored the diagnostic value of miR-210 as a potential diagnostic cancer biomarker to detect various cancers in patients. However, the results of its diagnostic accuracy and reliability in individual studies are still inconsistent. Therefore, we conducted this updated pooled analysis to derive a more reliable conclusion of the overall accuracy of miR-210 in cancer detection and diagnosis. A comprehensive literature search was performed using the PubMed, Cochrane Library, Web of Science, China National Knowledge Infrastructure, and Wanfang databases. The quality of all eligible studies was scored according to Quality Assessment of Diagnostic Accuracy Studies-2 guidelines. The bivariate mixed model was applied to pooled sensitivity, specificity, likelihood ratios, and diagnostic ORs. The summary receiver operator characteristic (SROC) curve and the hierarchical SROC models were used to check overall diagnostic performance. Thirty articles with 2,304 patients and 1,673 controls were included in this study. The pooled parameters calculated from all studies are as follows: sensitivity -0.74 (95% CI: 0.68–0.79), specificity -0.79 (95% CI: 0.74–0.83), positive likelihood ratio -3.57 (95% CI: 2.85–4.47), negative likelihood ratio -0.32 (95% CI: 0.26–0.40), diagnostic OR -10.98 (95% CI: 7.55–15.98), SROC -0.84 (95% CI: 0.80–0.87). All of these results revealed that miR-210 had relatively moderate accuracy in distinguishing patients with various cancers from all other individuals. However, well-designed prospective studies with large sample sizes using different groups of the population are urgently warranted to confirm our findings.

microRNA-210, cancer, biomarker, diagnosis, meta-analysis, ROC

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]